ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 137

Willingness to Pay for Highly Effective Drug Treatments in Brazilian Rheumatoid Arthritis Patients

Cleandro Albuquerque1, Pedro Haddad2, Vander Fernandes3, Claudia Marques4, Sonia Fialho5, Adriana Kakehasi6, Fabio Jennings7, Claiton Brenol8, Lícia M. H. Mota9,10, Geraldo Castelar-Pinheiro2,11, Angela Duarte12, Iara Giroto13, Maria Raquel C. Pinto14, Mariana Toni15, Mirhelen Mendes Abreu16 and Marcos B. Ferraz17, 1Rheumatology, Hospital Universitário de Brasília - UnB, Brasília, Brazil, 2Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, Brazil, 3Universidade de Cuiabá, Cuiaba MT, Brazil, 4Disciplina de Reumatologia, Hospital das Clínicas - Universidade Federal de Pernambuco, Recife - PE, Brazil, 5Rodovia Virgílio Várzea 1510 B, Universidade Federal de Santa Catarina, Florianópolis, Brazil, 6Rua Astolfo Vieira de Resende, Faculdade de Medicina - UFMG, Belo Horizonte, Brazil, 7Disciplina de reumatologia, Universidade Federal de São Paulo, Sao Paulo, Brazil, 8Universidade Federal do Rio Grande do Sul, Porto Alegre RS, Brazil, 9Rheumatology, University Hospital, Faculty of Medicine, University of Brasília, Brasília/DF, Brazil, 10Hospital Universitário de Brasília - UnB, Brasília, Brazil, 11Discipline of Rheumatology, Rio de Janeiro State University, Rio de Janeiro, Brazil, 12Internal Medicine, Hospital das Clínicas - UFPE, Recife, Brazil, 13Universidade de Cuiabá, Cuiabá, Brazil, 14Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, 15Faculdade de Medicina - UFRGS, Porto Alegre, Brazil, 16Disciplina de Reumatologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 17Universidade Federal de São Paulo, São Paulo, Brazil

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Health care cost and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Health Services Research Poster I: Diagnosis, Management and Treatment Strategies

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Willingness to pay (WTP) is a technique used for valuing health benefits and individual preferences. Brazil’s national public health system (Sistema Único de Saúde) grants the population access to costly and effective drugs for the management of rheumatoid arthritis (RA). The aim of this study was to establish WTP valuations for highly effective drug treatments in Brazilian RA patients.

Methods: This cross-sectional multicenter study enrolled adult RA patients (ACR 1987 or ACR/EULAR 2010 criteria) from rheumatology outpatient clinics of the Brazilian public health system. Consecutive patients were asked to reveal the maximum monetary value they would be willing to pay, on a monthly basis, for a hypothetical new intravenous drug offering a 90% improvement in their general health, thus a highly effective drug. Two WTP elicitation tools were used: a payment scale and an open-ended format. Demographic, social and clinical data were gathered from each subject. Disease activity was estimated by DAS28 score and physical function was assessed by HAQ-DI. Descriptive statistics were calculated.

Results: From April 2014 to May 2015, 688 patients (87% female) were assessed in eight Brazilian centers from all over the country. Mean disease duration was 12.7 (8.7) years; mean DAS28 = 3.5 (1.4); mean HAQ-DI = 1.23 (0.8). Subjects had a median of 6 (0 to 21) years of schooling and median household income of US$ 610.3 (0 to 7,909.9) per month. Median WTP values were US$ 22.9 (Q1=11.5; Q3=91.6) on payment scale, and US$ 38.2 (Q1=22.9; Q3=76.3) on open-ended format. On payment scale, 4.2% (28/665) of the respondents assigned zero values for WTP. Overall, 12.4% (83/688) of the subjects added commentaries expressing no willingness to pay at all, regardless of the value (if any) assigned to the elicitation tools. The ratio between median WTP value (open-ended format) and median household income was 6.3%.

Conclusion: This study set WTP valuations of highly effective intravenous drug treatments for chronic, moderately active RA, in outpatient clinics of the Brazilian public health system. The typical population attending to those clinics had low educational and income profile, and had free access to health resources, including medicines, seldom expecting to pay directly for their treatment. The stated WTP values were low, in face of the well known high costs of treating RA patients. Nonetheless, as a proportion of household income, WTP values were in line with the average expenditure of Brazilian families with health resources.


Disclosure: C. Albuquerque, None; P. Haddad, None; V. Fernandes, None; C. Marques, None; S. Fialho, None; A. Kakehasi, None; F. Jennings, None; C. Brenol, None; L. M. H. Mota, None; G. Castelar-Pinheiro, Abbvie, 5,AstraZeneca, 5,GlaxoSmithKline, 5,Hospira, 5,Janssen Pharmaceutica Product, L.P., 5,Pfizer Inc, 5,RuiYi, 5,Sanofi-Aventis Pharmaceutical, 5; A. Duarte, None; I. Giroto, None; M. R. C. Pinto, None; M. Toni, None; M. Mendes Abreu, None; M. B. Ferraz, None.

To cite this abstract in AMA style:

Albuquerque C, Haddad P, Fernandes V, Marques C, Fialho S, Kakehasi A, Jennings F, Brenol C, Mota LMH, Castelar-Pinheiro G, Duarte A, Giroto I, C. Pinto MR, Toni M, Mendes Abreu M, B. Ferraz M. Willingness to Pay for Highly Effective Drug Treatments in Brazilian Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/willingness-to-pay-for-highly-effective-drug-treatments-in-brazilian-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/willingness-to-pay-for-highly-effective-drug-treatments-in-brazilian-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology